Camurus announced today that it has entered into an option and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). The agreement is for the evaluation and development of hemophilia therapeutics with Camurus´ proprietary FluidCrystal® nanoparticle delivery technology. According to the terms of the agreement, Camurus will receive an upfront payment, development milestones and royalty payments.
"We are very pleased to enter into this collaboration with Wyeth, where our combined expertise and resources will be directed at improvements of essential product features and the quality-of-life of the target patient group" said Fredrik Tiberg, President & CEO of Camurus. Wyeth is a major pharmaceutical company with one of the strongest biotech product pipelines globally. Camurus has a strategic focus in this area with several ongoing development projects of protein and peptide therapeutics using its FluidCrystal® delivery technologies. "The Wyeth collaboration will focus on developing advanced hemophilia therapeutics and is another step towards our goal of establishing a set of strategic partnerships with leading biopharmaceutical companies."
Camurus AB is a life science company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. The company's FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in development programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and has currently three products in clinical development.